𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment with levodopa and risk for malignant melanoma

✍ Scribed by Jørgen H. Olsen; Karina Tangerud; Lene Wermuth; Kirsten Frederiksen; Søren Friis

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
64 KB
Volume
22
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

A large follow‐up study in Denmark of 14,088 patients in whom Parkinson's disease was diagnosed at hospital showed a twofold higher incidence of malignant melanoma in these patients than in the general population. In a nested case–control study of 45 patients with malignant melanoma, 97 patients with nonmelanoma skin cancer, and 172 control subjects, we investigated the hypothesis that treatment with levodopa increases the risk for skin cancer. Information on diagnoses and treatment was retrieved from medical records. We observed a significant fourfold to fivefold increase in the risk for malignant melanoma in a subgroup of patients with a probable diagnosis of idiopathic Parkinson's disease as compared with other patients. There was apparently no effect of levodopa on the risk for malignant melanoma as indicated by an odds ratio of 1.0 (95% confidence interval, 0.8–1.3) per 1,000 g cumulative intake of the drug. We conclude that the increased rate of malignant melanoma observed in patients treated at hospital for Parkinson's disease is restricted to those with idiopathic Parkinson's disease, however, unrelated to the treatment with levodopa. © 2007 Movement Disorder Society

📜 SIMILAR VOLUMES

Individual treatment for malignant melan
Individual treatment for malignant melanoma
✍ Hiram C. Polk Jr. 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 298 KB

Much has been learned in the recent decade about the predictable biologic behavior of cutaneous malignant melanoma. Indeed, such knowledge permits highly individualized treatment based on simple demographic data on the patient, location of the lesion, and its thickness according to the Breslow scale

Treatment of neuroleptic malignant syndr
Treatment of neuroleptic malignant syndrome with levodopa
✍ K. Otani; K. Mihara; T. Kondo; M. Okada; S. Kaneko; Y. Fukushima 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 400 KB

Seven consecutive episodes of neuroleptic malignant syndrome in five cases were treated with 50-600 mg/day (mean 342 mg/day) of levodopa. In four episodes active pharmacological treatment was initiated with levodopa, while in the remaining three episodes it was introduced because of poor therapeutic

Treatment of malignant melanoma
Treatment of malignant melanoma
✍ K. Fortýn; V. Hruban; V. Horák 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB 👁 2 views
Occupation and the risk of malignant mel
Occupation and the risk of malignant melanoma
✍ Ira A. Pion; Darrell S. Rigel; Lawrence Garfinkel; Mark K. Silverman; Alfred W. 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 654 KB

Background. The incidence of malignant melanoma is increasing rapidly. The risk for development of malignant melanoma has been reported to be higher in persons of higher socioeconomic status. Methods. This case-control study explores the relation between occupation and malignant melanoma relative r